Jazz Pharma PLC (NASDAQ:JAZZ) Earnings Model

JAZZ Consensus-Based Earnings Model.xlsx
File Size: 88 kb
File Type: xlsx
Download File
    Latest Update: July 7, 2016​ 
    This model needs an update to include the latest results...Feel free to update the model yourself, or sign-up to get an email alert after an update has been posted.
    ​Model Tier: Tier 2, Consensus-based model. 
    ​Model Created by: Ray Ga Ming Li. Ray is a member of our Northeastern University Modeling Intern Team. 
    ​    Click here to visit Ray's contributor page.
    ​Financial Modeling Approach: ​This model predicts revenue by drug, and then uses ratio analysis to build the income statement and project future earnings.

Models From Our Community 

Contributor Model by: Frank DePinto​
Last Update: November 20, 2016
View on Jazz: Bearish
Summary of Model Estimates: Updated Q32016 financials and lowered assumptions for 2017 revenue and EPS assumptions. According to commentary in the 10-K, Jazz is facing increasing threats from generic competition. The firm is also too reliant for my liking on sales of Xyrem, the primary drug facing generic competition. I also don't believe that Jazz is developing drugs in areas that are poised for tremendous patient growth or areas of unmet medical need. It seems like a majority of their clinical trial outlook is related to new indications for existing drugs in their portfolio. All in all, I don't necessarily have the most upbeat outlook for Jazz Pharmaceuticals for FY2017.
Click here to visit Frank's contributor page.
Frank DePinto JAZZ Model.xlsx
File Size: 88 kb
File Type: xlsx
Download File
StockTwits

Gutenberg Modeling Guide

New to earnings modeling?
​Our modeling guide demonstrates step-by-step how to create a financial model, similar to the models maintained by Wall Street Analysts.
Paperback
eBook

Become a Contributor

Step 1) Download the model above.
Step 2) Change the blue input cells.
Step 3) Submit your model for review.
Share on StockTwits